Now, researchers at Tulane University have developed the first vaccine shown to successfully protect nonhuman primates from melioidosis. The findings, published in Nature Communications, are a key step toward human clinical trials and preventing a bacterial infection that's often resistant to treatment—and which public health experts see spreading to areas it was not previously found.